In vitro Thrombolytic Potential of Actinoprotease from Marine Streptomyces violaceus VITYGM.
Back ground: One of the most prevailing diseases that required effective drug as therapeutic purposes is cardiac related illness includes myocardial infarction Current scenario makes enzyme to raises their sector towards therapeutic as effective active component for such diseases.


OBJECTIVE
The main aim of the study was to isolate, screen, characterize and produce an extracellular thrombolytic protease from marine actinomycetes.


METHODS
Marine actinomycete was isolated and characterized on the basis of morphological, biochemical, and molecular characterization. The primary screening for protease activity was done by casein hydrolysis method followed by radial caseinolytic assay. The actinoprotease was partially purified using ammonium sulfate precipitation technique followed by dialysis and Sephadex G-50 gel permeation chromatography.


RESULTS
16srDNA sequencing and BLAST search analysis of the sequence revealed close affiliation with Streptomyces genera and identified as Streptomyces violaceus VITYGM with 99% similarity. The specific activity of purified protease was found to be 1437 units/mg along with purification fold up to 1.5 times. The blood clot lysis activity was compared with the standard and found to lyse the blood clot with 97.43%. Till now very less evidences have been reported on actinoprotease. A single peak at retention time 0.9 min observed on high performance liquid chromatography (HPLC) confirmed the homogeneity of the preparation.


CONCLUSIONS
This is the first study to report on actinoprotease from Streptomyces violaceus VITYGM. This study emphasizes the potency of novel actinoproteases as active compound in drugs for the treatment of cardiovascular diseases.
V
V
Mohanasrinivasan
S
S
Yogesh
A
A
Govindaraj
S Jemimah
SJ
Naine
School of Biosciences and Technology, VIT University,Vellore- 632 014, Tamil Nadu, India.
C Subathra
CS
Devi
D001777:Blood Coagulation / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000188:drug therapy; D002364:Caseins / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000302:isolation & purification / Q000494:pharmacology*; D006801:Humans; D010447:Peptide Hydrolases / Q000302:isolation & purification / Q000494:pharmacology*; D013302:Streptomyces / Q000201:enzymology*
D002364:Caseins; D005343:Fibrinolytic Agents; D010447:Peptide Hydrolases
Actinoproteases; Streptomyces violaceus; cardiovascular diseases; halophilic; purification; thromobolytics